Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 8/20 | 0.75 |
| ▸ | NFKBIA | P25963 | 7/20 | 0.75 |
| ▸ | SLC40A1 | Q9NP59 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | MDM4 | O15151 | 1/20 | 0.71 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973669 | 0.87 | RELA (0.59) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL11972939 | 0.86 | RELA (1.00) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL11973295 | 0.83 | SLC40A1 (1.00) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL11973681 | 0.80 | SLC40A1 (0.73) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL29255668 | 0.78 | SLC40A1 (0.68) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL30854820 | 0.78 | SLC40A1 (0.68) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL11972815 | 0.77 | SLC40A1 (0.68) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL11973639 | 0.77 | SLC40A1 (1.00) | NFKBIASLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL31115266 | 0.76 | SLC10A6 (0.60) | RELANFKBIASLC40A1MEN1KMT2A | |
| SCHEMBL1031078 | 0.76 | PDE10A (0.59) | MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | RELA 1102/4885NFKBIA 277/4885SLC40A1 2/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | RELA 1102/4885NFKBIA 277/4885SLC40A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.